The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 – Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing site.
Radiopharmaceutical manufacturing is a complex business, both in the technical aspects and the regulation of the use of radiation. Although the industrial production and use of medical isotopes are a lot less complicated than other nuclear/radioactive technology applications, there is still a significant barrier to entry to handle medical radiation at large scale, particularly in Europe.
Over the past few years, Telix has established productive relationships with some of the most important radiopharmaceutical manufacturers in Europe. The European market, although fragmented and complex due to the variation in radiation safety and handling laws amongst member states, is also one of the most important global markets for Telix’s products and is extremely vibrant from an innovation perspective. The basic challenge is that no single manufacturer has the production capacity to really deliver on Telix’s needs in Europe for both diagnostic and therapeutic products. This is partially due to the aforementioned fragmentation, but also because the industry overall is still nascent. Hence, there are relatively few examples of commercial products that have driven the business case for building production capacity until now.
Of course, all of this is about to change and there are a large number of products in the pipeline (close to 100) companies such as Telix, Novartis, ITM and others.
The decision by Telix to acquire the Seneffe site from Eckert and Ziegler, a leading isotope production company was not a trivial decision. The site was originally constructed in the late 1990s to make palladium and iodine brachytherapy seeds for treating cancer. The palladium (103Pd) was actually made onsite in two large cyclotron bunkers and this accounted for much of the radioactivity and contamination at the site. The site ceased making brachytherapy seeds in 2008 and the prior owners partially decommissioned the site, with the exception of the two cyclotron bunkers, which (it was reasoned) would not warrant removal because a new owner would want to install new cyclotrons and this would, in turn, recommence irradiation of those bunkers.
So why would Telix want to acquire such a site?
Well, the beauty of the site is that it comes with a very deep license – in fact, one of the deepest private radiation licenses for medical isotopes in Europe. Today it would be challenging to obtain approval to build and commission the site, let alone obtain approval to handle a large amount of medical radiation on an operational basis. Moreover, the site is configured to handle both radioactive metals and radio-halogens (like iodine), which are gaseous and volatile. This is a unique fit with Telix’s product portfolio which has both iodinated compounds (i.e. TLX101 for treating glioblastoma, a form of brain cancer) as well as both diagnostic (TLX250-CDx for imaging renal cancer with 89Zr) and therapeutic (TLX591 for treating prostate cancer with 177Lu) radiometal use.
What Telix has acquired is essentially a completely blank canvas for manufacturing operations. Telix has submitted a new operational plan to the nuclear regulators and waste management authorities. The license has been upgraded to reflect the operational plan for the site and Telix has commenced the process of removing one of the old cyclotrons (which is no longer operationally feasible) to make way for the installation of new production capabilities. It is worth noting that the site has capacity for up to 8 medium-energy cyclotrons on site. That’s a LOT of production firepower if Telix needs it in the future, and very rare!
So, what next?
Well, over the next 12-15 months the focus is to get the old cyclotrons out and pave the way for new production systems. Telix made a commitment to the various regulators that the company would get a move on with this as part of the acquisition of the site, and this work has started. Both the prostate and kidney imaging agents will be produced and distributed out of this site (TLX591-CDx and TLX250-CDx) and Telix needs to be ready in about 18 months to produce these products in commercial quantities. Our manufacturing team has a big job ahead!
Personally, I love this site. Its location is amazing and we couldn’t have asked for a site layout better suited to our product pipeline. We can even hit 5 countries and a couple of dozen major hospitals within about 100km driving radius so in addition to working with our network of distribution and logistics companies, we expect to some degree of product distribution directly out of the site. This is not only good for cost-effective commercial operations but great for facilitating research collaborations. Brussels and Charleroi airports (20 minutes away) get us to the rest of Europe and beyond
Christian Behrenbruch, Ph.D
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...
Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021
Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...
Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...
Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility
8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...
Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report
Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...
Telix FY2020 Results and Company Update Conference Call
Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.
Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...
Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium
3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...
Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process
Melbourne (Australia) – 14 April 2021. Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced...